Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells.

Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Print ISSN: 0007-0920 (Print) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.

Neoplastic Cells, Circulating*; Biomarkers, Tumor/*blood ; Carcinoma, Hepatocellular/*diagnosis ; Liver Neoplasms/*diagnosis ; Neoplasm Proteins/*genetics ; RNA, Messenger/*blood; Adult ; Aged ; Antigens, Neoplasm ; Carcinoma, Hepatocellular/blood ; Female ; Humans ; Liver Neoplasms/blood ; Male ; Melanoma-Specific Antigens ; Middle Aged ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; Sensitivity and Specificity ; Tumor Cells, Cultured ; alpha-Fetoproteins/analysis

The members of MAGE gene family are highly expressed in human hepatocellular carcinoma (HCC). In the present study, we tested the tumour-specific MAGE-1 and MAGE-3 transcripts in the peripheral blood of HCC patients by nested RT-PCR to detect the circulating tumour cells and evaluate their potential clinical implication. Of 30 HCC patients, the positive rate of MAGE-1 and MAGE-3 transcripts was 43.3% (13 out of 30) and 33.3% (10 out of 30) in PBMC samples, whilst the positive rate was 70% (21 out of 30) and 53.3% (16 out of 30) in the resected HCC tissue samples, respectively. The positivity for at least one MAGE gene transcript was 63.3% (19 out of 30) in PBMC samples of HCC patients and 83.3% (25 out of 30) in the resected HCC tissue samples. MAGE-1 and/or MAGE-3 mRNA were not detected in the PBMC of those patients from whom the resected HCC tissues were MAGE-1 or MAGE-3 mRNA negative, nor in the 25 PBMC samples from healthy donors. The detection of MAGE transcripts in PBMC was correlated with the advanced stages and tumour size of the HCC, being 82.4% (14 out of 17) in tumour stages III and IVa, 56.6% (five out of nine) in stage II, and null (nought out of four) in stage I. The serum alpha-FP in 33.3% (10 out of 30) of HCC patients was normal or slightly elevated (< 40 ng ml(-1)). However, six of these 10 patients (alpha-FP < 40 ng ml(-1)) were MAGE-1 and /or MAGE-3 mRNA positive in their PBMC. The follow-up survey of MAGE mRNA in PBMC was performed in 12 patients. Seven patients with persistent MAGE-1 and/or MAGE-3 mRNA positive or from negative turned to positive died because of metastasis and/or recurrence. In striking contrast, all four patients with MAGE-1 and/or MAGE-3 mRNA from positive turned to negative and one patient with persistent MAGE-3 transcript negative are alive after last test. Collectively, detection of MAGE transcripts with follow-up survey in PBMC is a feasible and reliable assay for the early prediction of the relapse and prognosis of the HCC patients.

Gastroenterology. 1994 Jan;106(1):239-42. (PMID: 8276187)
Blood. 1991 Jul 15;78(2):255-8. (PMID: 2070062)
Cancer Res. 1998 Feb 15;58(4):743-52. (PMID: 9485030)
Zhonghua Wai Ke Za Zhi. 2000 Sep;38(9):693-6. (PMID: 11832142)
Br J Cancer. 1997;76(5):628-33. (PMID: 9303362)
Dig Dis Sci. 2000 Jul;45(7):1376-82. (PMID: 10961717)
Proc Natl Acad Sci U S A. 1995 May 23;92(11):4987-91. (PMID: 7761436)
Ann Surg. 1997 Jul;226(1):43-50. (PMID: 9242336)
Gastroenterology. 1994 Aug;107(2):630-1. (PMID: 8068150)
Eur J Cancer. 1991;27(6):762-5. (PMID: 1676900)
Hepatology. 1999 Mar;29(3):879-82. (PMID: 10051492)
Hepatology. 1995 Feb;21(2):403-7. (PMID: 7843713)
Immunogenetics. 1994;40(5):360-9. (PMID: 7927540)
Hepatology. 1994 Dec;20(6):1418-25. (PMID: 7527002)
Br J Cancer. 1997;75(6):928-33. (PMID: 9062418)
Hepatology. 1996 Dec;24(6):1437-40. (PMID: 8938177)
Cancer. 1999 Mar 15;85(6):1234-40. (PMID: 10189127)
Genomics. 1997 Dec 15;46(3):397-408. (PMID: 9441743)
J Invest Dermatol. 1993 Dec;101(6):887-9. (PMID: 8245518)
Lancet. 1991 Nov 16;338(8777):1227-9. (PMID: 1719320)
Int J Cancer. 1995 Feb 8;60(4):471-7. (PMID: 7530237)
Science. 1991 Dec 13;254(5038):1643-7. (PMID: 1840703)
Cancer. 1995 May 1;75(9):2214-9. (PMID: 7536120)
Cancer Res. 1994 Dec 15;54(24):6306-10. (PMID: 7527294)
Int J Cancer. 1996 Dec 11;68(6):739-43. (PMID: 8980176)
Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S18-20. (PMID: 8899163)
Liver. 1999 Apr;19(2):110-4. (PMID: 10220740)
J Urol. 1995 Mar;153(3 Pt 1):573-7. (PMID: 7532229)
Br J Cancer. 1995 Jul;72(1):155-9. (PMID: 7599046)
Cancer. 1996 Mar 15;77(6):1214-9. (PMID: 8635146)
J Clin Oncol. 1995 Aug;13(8):2109-16. (PMID: 7636555)

0 (Antigens, Neoplasm)
0 (Biomarkers, Tumor)
0 (MAGEA1 protein, human)
0 (MAGEB2 protein, human)
0 (Melanoma-Specific Antigens)
0 (Neoplasm Proteins)
0 (RNA, Messenger)
0 (alpha-Fetoproteins)

Date Created: 20020222 Date Completed: 20020307 Latest Revision: 20220331

20240829

PMC2746529

10.1038/sj.bjc.6600016

11857021